Help employers find you! Check out all the
OWASSO, Okla., Aug. 5, 2014 /PRNewswire/ -- The Idaho Society of Clinical Oncology (ISCO) had its first Board of Directors retreat in Sun Valley, ID on July 25-26, 2014. ISCO decided to explore the formation of a state wide tumor board concentrating on cutting edge molecular techniques to provide personalized cancer therapy to the patients in in the state of Idaho. Tumor board is a patient care conference in which physicians from different medical specialties review and discuss the medical condition and treatment options of a patient.
During the retreat Binay Shah, MD assumed the role of President for the Board term 2014-2016 from Dane Dickson, MD. Dr. Dickson will continue to be an energetic leader and member of ISCO. Dr. Dickson said, "Being able to match a precise treatment to individual patient is the future of oncology and all medicine. Doing so will limit toxicities and give better gains. Yet, in order to implement this lofty future, we need to come together as states and regions... ISCO can serve as a prototype and leader to the nation through this state wide personalized medicine endeavor."
The focus for the retreat was to discuss strategies to improve the care of cancer patients in Idaho. Other activities during the retreat also included developing subcommittees including one focusing on Public Policy and Advocacy, to engage all the stakeholders in oncology.
Idaho Society of Clinical Oncology (ISCO) is a 501c(3) non-profit organization and a state affiliate of American Society of Clinical Oncology, the largest organization of clinical oncologists with more than 30000 members. ISCO is devoted to the improvement of hematologic and oncologic care of patients. For more information, visit http://idsco.org/.
For more information, or to schedule an interview with any of our board members, please contact Mary Jo Richards at MaryJo@mjexecmgmt.com or (918) 261-8951. www.idsco.org
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
SOURCE Idaho Society of Clinical Oncology